LENSAR (NASDAQ:LNSR – Get Rating) and InspireMD (NYSE:NSPR – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.
Earnings and Valuation
This table compares LENSAR and InspireMD's revenue, earnings per share and valuation.
Get LENSAR alerts:| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| LENSAR | $34.46 million | 1.81 | -$19.60 million | ($2.40) | -2.36 |
| InspireMD | $4.49 million | 3.28 | -$14.92 million | ($2.22) | -0.80 |
InspireMD has lower revenue, but higher earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
56.0% of LENSAR shares are owned by institutional investors. Comparatively, 2.1% of InspireMD shares are owned by institutional investors. 19.0% of LENSAR shares are owned by insiders. Comparatively, 3.8% of InspireMD shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.Analyst Ratings
This is a breakdown of current ratings and target prices for LENSAR and InspireMD, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| LENSAR | 0 | 0 | 2 | 0 | 3.00 |
| InspireMD | 0 | 0 | 0 | 0 | N/A |
LENSAR currently has a consensus price target of $14.00, suggesting a potential upside of 147.35%. Given LENSAR's higher possible upside, equities research analysts clearly believe LENSAR is more favorable than InspireMD.
Risk and Volatility
LENSAR has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500. Comparatively, InspireMD has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500.
Profitability
This table compares LENSAR and InspireMD's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| LENSAR | -63.71% | -45.47% | -37.06% |
| InspireMD | -334.66% | -54.85% | -46.01% |
Summary
LENSAR beats InspireMD on 8 of the 13 factors compared between the two stocks.
About LENSAR
(Get Rating)
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
About InspireMD
(Get Rating)
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Receive News & Ratings for LENSAR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENSAR and related companies with MarketBeat.com's FREE daily email newsletter.